Market Research Report
Closed System Drug Transfer Devices to 2026
|Published by||Greystone Research Associates||Product code||985625|
Delivery time: 1-2 business days
|Closed System Drug Transfer Devices to 2026|
|Published: February 2, 2021||Content info:||
The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.